U.S. Generic Drug Outlook 2018 anticipates market growth

The recently released U.S. Generic Drug Market Outlook 2018 revealed a steadily growing market for generics in terms of prescriptions and revenue, and provided an in-depth analysis on the current status of the market.

Conducted by RNCOS, the market outlook report said the U.S. generics market generated $43.5 billion in revenue in 2013 and is expected to grow approximately 11 percent by 2018. The growth is due to factors such as demand for cost-effective medications, an aging population, expiration of drug patents, enhanced government support and rising health care spending. 

The U.S. pharmaceutical market is already the largest in the world, and it accounts for approximately 45 percent of the global generics market.

The outlook report revealed that in the coming years the generics market in the United States could experience healthy growth in multiple areas, including drugs to treat respiratory, thyroid, ulcers, oncology and cholesterol disorders. In addition, support from the U.S. government will spur future generic market growth, according to the report.

The report evaluates facts and figures about market size, share, growth, technology trends and regulatory environment so that clients have an overview of the generic market. In addition, it provides analysis of developing market trends, competitive landscape and future outlook; and provides valuable information for potential generic companies and investors